<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Osamura, Robert Yoshiyuki</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Updated Guidelines for Classifying Gastroenteropancreatic Neuroendocrine Neoplasms</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the nomenclature of neuroendocrine tumors (NETs), according to the updated 2010 World Health Organization (WHO) classification. This scheme classifies NETs based on prognostication by their proliferative activities, with respect to mitotic rate and Ki-67 labeling index. Since this accounts for tumor grading and prognosis, it facilitates development of treatment strategies, with somatostatin receptor 2a-positive tumors in particular demonstrating improved response to therapy with somatostatin analogs.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>